For research use only. Not for therapeutic Use.
Trientine, also known as Triethylenetetramine, abbreviated TETA and trien, is a chelating agent, and is used to bind up and remove copper in the body to treat Wilson/’s disease, particularly in those who are intolerant to penicillamine. Some recommend trientine as first-line treatment, but experience with penicillamine is more extensive. Trientine can also be used as stabilizer for epoxy resins, as ampholyte for isoelectric focusing and as chelating agent for copper in hepatolenticular degeneration.
| Catalog Number | R062426 |
| CAS Number | 38260-01-4 |
| Synonyms | N,N’-Bis(2-aminoethyl)-1,2-ethanediamine Dihydrochloride; Cuprid; N,N’-Bis-(2-aminoethyl)-1,2-ethanediamine Dihydrochloride; Syprine; TTH; Trien dihydrochloride; Trientine Dihydrochloride; Trientine Hydrochloride; Triethylenetetramine Dihydrochloride |
| Molecular Formula | C6H20Cl2N4 |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine;dihydrochloride |
| InChI | InChI=1S/C6H18N4.2ClH/c7-1-3-9-5-6-10-4-2-8;;/h9-10H,1-8H2;2*1H |
| InChIKey | WYHIICXRPHEJKI-UHFFFAOYSA-N |
| SMILES | C(CNCCNCCN)N.Cl.Cl |
| Reference | </br>1:Solid state stability and solubility of triethylenetetramine dihydrochloride. Henriet T, Gana I, Ghaddar C, Barrio M, Cartigny Y, Yagoubi N, Do B, Tamarit JL, Rietveld IB.Int J Pharm. 2016 Sep 10;511(1):312-21. doi: 10.1016/j.ijpharm.2016.06.140. Epub 2016 Jul 1. PMID: 27377012 </br>2:Controllable synthesis of thiol-capped CdTe nanoparticles for optical sensing of triethylenetetramine dihydrochloride. Huy BT, Kumar AP, Seo MH, Kim JD, Lee YI.J Nanosci Nanotechnol. 2014 Oct;14(10):7662-7. PMID: 25942844 </br>3:Subacute and chronic toxicity studies of triethylenetetramine dihydrochloride (TJA-250) by oral administration to F-344 rats. Yanagisawa T, Maemura S, Sasaki H, Endo T, Okada M, East PW, Virgo DM, Creasy DM.J Toxicol Sci. 1998 Oct;23 Suppl 4:619-42. PMID: 9836186 </br>4:Subchronic toxicity of triethylenetetramine dihydrochloride in B6C3F1 mice and F344 rats. Greenman DL, Morrissey RL, Blakemore W, Crowell J, Siitonen P, Felton P, Allen R, Cronin G.Fundam Appl Toxicol. 1996 Feb;29(2):185-93. PMID: 8742314 </br>5:Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilson/’s disease. Kodama H, Meguro Y, Tsunakawa A, Nakazato Y, Abe T, Murakita H.Tohoku J Exp Med. 1993 Jan;169(1):59-66. PMID: 8211970 Free Article</br>6:Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson/’s disease. Siegemund R, Lössner J, Günther K, Kühn HJ, Bachmann H.Acta Neurol Scand. 1991 Jun;83(6):364-6. PMID: 1887758 </br>7:Determination of triethylenetetramine dihydrochloride in aqueous solution by reversed-phase ion-pairing high performance liquid chromatography and conductivity detection. Hansen EB Jr, Rushing LG, Thompson HC Jr.J Anal Toxicol. 1985 Jul-Aug;9(4):167-71. PMID: 4033073 </br>8:The effect of triethylenetetramine dihydrochloride on the in vivo susceptibility of Pseudomonas aeruginosa to gentamicin. Light B, Riggs HG Jr.J Antibiot (Tokyo). 1979 Aug;32(8):834-8. PMID: 115822 Free Article</br>9:[Treatment of Wilson/’s disease using triethylenetetramine dihydrochloride (TETA)]. Hauftová D, Körbel J, Jancík F, Kuhr I, Ferenc M.Cesk Gastroenterol Vyz. 1978 Dec;32(8):538-9. Czech. No abstract available. PMID: 737791 </br>10:Effect of triethylenetetramine dihydrochloride on the antibiotic susceptibility of Pseudomonas aeruginosa. Light B, Riggs HG Jr.Antimicrob Agents Chemother. 1978 Jun;13(6):979-84. PMID: 98108 Free PMC Article |
